Core Insights - The revenue growth of ARCALYST is projected at 62% for the full year 2025, driven by increased adoption of IL-1 alpha and beta inhibition as a second-line treatment after NSAID and colchicine failure [1] - Management credits the commercial success to a shift in treatment paradigms, supported by the 2025 ACC clinical guidance that endorses IL-1 inhibition as a preferred second-line approach [1] - The company is utilizing its profitable ARCALYST franchise to fund strategic investments in digital marketing, AI-driven physician targeting, and the development of internally discovered assets [1] Operational Focus - The operational focus has shifted towards unlocking the next phase of growth by increasing penetration in the multiple recurrence market and expanding into the first recurrence population [1] - Strategic positioning in the recurrent pericarditis market is being enhanced through the development of KPL-387, which aims to meet patient needs with less frequent monthly dosing and auto-injector administration [1] Market Dynamics - Market dynamics indicate that growth at specialized pericardial disease centers is outpacing other sites, leading management to explore ways to expand the impact of these high-volume centers [1]